Mass Spectrometry in Myeloma: Can a Blood Test Reduce Bone Marrow Biopsies? | IMS 2026

Can Resistance Exercise Help Heal Bone Lesions in Multiple Myeloma? | IMS 2026

Can CD4/CD8 T-Cell Ratio Predict Parkinson-Like Side Effects After BCMA CAR-T in Myeloma | IMS 2026

Can Iberdomide Replace Revlimid in Newly Diagnosed Myeloma? KId Results | IMS 2026

MajesTEC-3: Could Teclistamab + Daratumumab Lead to a “Functional Cure” in Myeloma? | IMS 2026

Infection Prevention in Multiple Myeloma: What Patients Need to Know | IMS 2026

MajesTEC-5: High MRD-Negative Rates With Talquetamab Combo in Newly Diagnosed Myeloma | IMS 2026

Top 5 Things Newly Diagnosed Multiple Myeloma Patients Should Know | IMS 2026

Social Security Disability and Supplemental Income Benefits | Dollars & Diagnosis

CARTITUDE-2: Can Earlier Cilta-Cel CAR-T Lead to Long-Term Remission or Cure in Myeloma? | IMS 2026

ENDURANCE Trial: Can Myeloma Patients Stop Revlimid Maintenance After 2 Years? | IMS 2026

Iberdomide Plus Dara After Transplant: Early Safety and Results | IMS 2026

Multiple Myeloma Side Effects: When Should You Call Your Care Team? | IMS 2026

Second Cancers After Myeloma: Who Faces Higher Risk? | IMS 2026

How Is Myeloma Treatment Changing? Quadruplets, CAR-T, Bispecifics and New Therapies | IMS 2026

Personalized Vaccine for Smoldering Myeloma: Could It Prevent Progression? | IMS 2026